TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33337649

Group type: EXPERIMENTAL
Intervention: High-frequency (HF) rTMS on the left dorsolateral prefrontal cortex (DLPFC) (80 trains, 30 pulses per train, 12 s intertrain interval, 2400 pulses per session)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Low-frequency (LF) rTMS on the right DLPFC (2 trains, 700 pulses per train, 1 s intertrain-interval, 1400 pulses per session)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Low-frequency (LF) rTMS on the right DLPFC
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: High-frequency (HF) rTMS on the left DLPFC
Number of subjects: 146
Study: 35856162

Group type: EXPERIMENTAL
Intervention: Terlipressin (1.3 μg/kg/hour for 24 h)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 22
Study: 34871513

Group type: EXPERIMENTAL
Intervention: Intracoronary injection of nicorandil
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 90
Study: 35146573

Group type: EXPERIMENTAL
Intervention: Tumor enhancement ratio (TER)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Model based on TER
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Modified high-risk and non-high risk grouping based on recurrence risk score (cut-off value: 1.75)
Number of subjects: 282
Study: 33967049

Group type: EXPERIMENTAL
Intervention: fNIRS index in non-dementia controls (NDC)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: fNIRS index in mild cognitive impairment (MCI) patients
Number of subjects: 63
Study: 32546247

Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition (PN) initiated within 24 hours after PICU admission
Number of subjects: 1158

Group type: EXPERIMENTAL
Intervention: Late parenteral nutrition (PN) withheld for up to 1 week in the PICU
Number of subjects: 1158

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 1158

Group type: EXPERIMENTAL
Intervention: Parents' own HRQoL
Number of subjects: 1158
Study: 33647343

Group type: COMPARATOR
Intervention: Single endoscopist (SE)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Nurse-assisted (NA)
Number of subjects: 500
Study: 32334702

Group type: EXPERIMENTAL
Intervention: rfMDA
Number of subjects: 8948

Group type: COMPARATOR
Intervention: RACD
Number of subjects: 8948

Group type: EXPERIMENTAL
Intervention: RAVC
Number of subjects: 8948

Group type: COMPARATOR
Intervention: No RAVC
Number of subjects: 8948

Group type: EXPERIMENTAL
Intervention: rfMDA plus RAVC
Number of subjects: 8948

Group type: COMPARATOR
Intervention: RACD only
Number of subjects: 8948
Study: 34320822

Group type: EXPERIMENTAL
Intervention: MMB plus usual depression care (MMB+UDC)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Usual depression care (UDC)
Number of subjects: 389
Study: 34119655

Group type: EXPERIMENTAL
Intervention: AngioJet-PCDT
Number of subjects: 364
Study: 33963911

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 56

Group type: COMPARATOR
Intervention: Direct MT (no alteplase)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Higher eTICI scores
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Administration of alteplase
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Additional alteplase
Number of subjects: 56
Study: 36494006

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 912

Group type: COMPARATOR
Intervention: Chemotherapy (investigator's choice of paclitaxel, docetaxel, or vinflunine)
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Pembrolizumab in KEYNOTE-052
Number of subjects: 912
Study: 34000257

Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 11558

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 11558
Study: 32703266

Group type: EXPERIMENTAL
Intervention: Pre‐pregnancy BMI (per 5‐unit increase)
Number of subjects: 1583

Group type: EXPERIMENTAL
Intervention: Pre‐pregnancy overweight
Number of subjects: 1583

Group type: EXPERIMENTAL
Intervention: Pre‐pregnancy obesity
Number of subjects: 1583

Group type: COMPARATOR
Intervention: Excessive GWG vs. non-excessive GWG
Number of subjects: 1583

Group type: EXPERIMENTAL
Intervention: GWG per 1 kg increase
Number of subjects: 1583
Study: 36270464

Group type: EXPERIMENTAL
Intervention: transcranial random noise stimulation (tRNS)
Number of subjects: 64
Study: 33453456

Group type: EXPERIMENTAL
Intervention: Vitamin C (1.5 g/6 h)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 32130809

Group type: EXPERIMENTAL
Intervention: Long-acting cabotegravir and rilpivirine (monthly intramuscular injections)
Number of subjects: 616

Group type: COMPARATOR
Intervention: Oral therapy (standard antiretroviral therapy)
Number of subjects: 616
Study: 35559498

Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone acetonide (GC group)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (PLA group)
Number of subjects: 8
Study: 35000582

Group type: EXPERIMENTAL
Intervention: Honey medicinal gel (unheated natural honey)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 48
Study: 34048095

Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment for 2 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Healthy horses (control group)
Number of subjects: 14
Study: 33045769

Group type: COMPARATOR
Intervention: Conventional ventilation (CV; tidal volume of 9‐10 mL/kg predicted body weight with no positive end‐expiratory pressure)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Protective ventilation (PV; tidal volume of 6‐8 mL/kg predicted body weight and 5 cmH₂O PEEP)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Protective ventilation (PV)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 42
Study: 35818757

Group type: EXPERIMENTAL
Intervention: SARUS CPR hood
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard equipment
Number of subjects: 15
Study: 34663784

Group type: EXPERIMENTAL
Intervention: Yohimbine administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36451616

Group type: EXPERIMENTAL
Intervention: Active‐tDCS (N=20 with pain)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham‐tDCS (N=20 with pain)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Active‐tDCS (N=20 without pain)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham‐tDCS (N=20 without pain)
Number of subjects: 80
Study: 33857914

Group type: EXPERIMENTAL
Intervention: Qing-Chang-Hua-Shi granules (125 g/day)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo (125 g/day)
Number of subjects: 119
Study: 36272243

Group type: EXPERIMENTAL
Intervention: Testosterone gel added to the interrupted microdose flare protocol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional microdose flare protocol
Number of subjects: 60
Study: 34619734

Group type: EXPERIMENTAL
Intervention: Oral azithromycin 1 g (group 1)
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Oral azithromycin 1 g with oral amoxicillin 2 g (group 2)
Number of subjects: 756

Group type: COMPARATOR
Intervention: Placebo (group 3)
Number of subjects: 756
Study: 32161233

Group type: EXPERIMENTAL
Intervention: CHX 0.12% mouthrinse (twice daily, 10 mL rinse for 30 s)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: CHX 0.20% mouthrinse (twice daily, 10 mL rinse for 30 s)
Number of subjects: 354

Group type: COMPARATOR
Intervention: No topical treatment (Control group)
Number of subjects: 354
Study: 35976200

Group type: EXPERIMENTAL
Intervention: Moving Stories program
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 185
Study: 32200009

Group type: EXPERIMENTAL
Intervention: Combined bleaching (CB) treatment
Number of subjects: 105

Group type: COMPARATOR
Intervention: Home bleaching (HB)
Number of subjects: 105

Group type: COMPARATOR
Intervention: In-office bleaching (IOB)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Combined bleaching (CB) and In-office bleaching (IOB)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: All bleaching protocols
Number of subjects: 105
Study: 35183806

Group type: EXPERIMENTAL
Intervention: Tailored open lung approach (OLA)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: End inspiratory pause (EIP) of 30%
Number of subjects: 32

Group type: COMPARATOR
Intervention: End inspiratory pause (EIP) of 10%
Number of subjects: 32
Study: 33663264

Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil
Number of subjects: 161
Study: 33583390

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-based therapy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Silymarin therapy
Number of subjects: 110
Study: 35137022

Group type: EXPERIMENTAL
Intervention: Psychological interventions to optimize treatment expectations (IA group, n = 30)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Multi-component intervention (IB group, n = 29) with psychological interventions plus additional treatment package
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard medical care (SMC, n = 29)
Number of subjects: 88
Study: 33689512

Group type: EXPERIMENTAL
Intervention: Group 1: 110 kV, 80 mA (enhanced cranial mode)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Group 2: 120 kV, 64 mA (lumbar spine mode)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Group 3: 120 kV, 25 mA (head/neck settings)
Number of subjects: 18
Study: 32333208

Group type: EXPERIMENTAL
Intervention: MARTAS (n=135)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Standard of Care (SOC) (n=139)
Number of subjects: 274
Study: 35484674

Group type: EXPERIMENTAL
Intervention: Bleaching subgroup
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combined subgroup
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Resin subgroup
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control subgroup
Number of subjects: 24
Study: 34559005

Group type: EXPERIMENTAL
Intervention: Dedicated CT lung screening viewer
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard PACS-like viewer
Number of subjects: 160
Study: 35501082

Group type: EXPERIMENTAL
Intervention: Antianaerobic antibiotics
Number of subjects: 0
Study: 34515439

Group type: EXPERIMENTAL
Intervention: Saline enemas twice daily until normal stooling pattern achieved (Group 1)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Erythromycin and enemas (Group 2)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Enemas only when symptoms observed (Group 3)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 67
Study: 33725465

Group type: EXPERIMENTAL
Intervention: Cycling at 80% V̇O2max
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cycling at 70% V̇O2max
Number of subjects: 21

Group type: COMPARATOR
Intervention: Running at 70% V̇O2max
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 21

Group type: COMPARATOR
Intervention: Cycling vs Running
Number of subjects: 21
Study: 32888740

Group type: EXPERIMENTAL
Intervention: Pentavalent vaccine (Quinvaxem)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hexavalent vaccine (Infanrix-hexa)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pentavalent vaccine (Quinvaxem) among TT-vaccinated mothers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary and booster vaccination
Number of subjects: 0
Study: 34529839

Group type: EXPERIMENTAL
Intervention: Esflurbiprofen plaster (SFPP)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Flurbiprofen tablets (FPT)
Number of subjects: 38
Study: 32115598

Group type: EXPERIMENTAL
Intervention: Randomized intervention providing repeated data feedback via email to volunteers
Number of subjects: 46

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 46
Study: 35108339

Group type: EXPERIMENTAL
Intervention: PfRAS immunization
Number of subjects: 0
Study: 32694328

Group type: EXPERIMENTAL
Intervention: Simulator training sessions (TraumaVision Virtual Reality Simulator)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no additional simulator training)
Number of subjects: 28
Study: 35009908

Group type: EXPERIMENTAL
Intervention: Harvard test
Number of subjects: 139

Group type: COMPARATOR
Intervention: No effort (Control Group Y)
Number of subjects: 139
Study: 32106963

Group type: EXPERIMENTAL
Intervention: MyHEARTSMAP self-assessment tool
Number of subjects: 795
Study: 34424021

Group type: EXPERIMENTAL
Intervention: If-then plans (behavioral intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CDC guidelines (control condition)
Number of subjects: 0
Study: 32385508

Group type: EXPERIMENTAL
Intervention: Intravenous delta-9-tetrahydrocannabinol (THC)
Number of subjects: 400
Study: 35153517

Group type: EXPERIMENTAL
Intervention: FlexDex™
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional rigid needle holder
Number of subjects: 40
Study: 33177437

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone
Number of subjects: 22

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Study treatments (both interventions)
Number of subjects: 22
Study: 34959253

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 34485058

Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Office visit
Number of subjects: 41
Study: 33025843

Group type: EXPERIMENTAL
Intervention: Chemotherapy + Hyperthermia
Number of subjects: 200

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 200
Study: 36188104

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 73

Group type: COMPARATOR
Intervention: Routine treatment (Control group)
Number of subjects: 73
Study: 33631065

Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg per kilogram of body weight)
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: Sarilumab (400 mg)
Number of subjects: 803

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: Pooled interleukin-6 receptor antagonists (tocilizumab and sarilumab)
Number of subjects: 803
Study: 32867199

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA supplementation (2.6 g EPA and 1.8 g DHA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: SRP alone (Control)
Number of subjects: 30
Study: 36429912

Group type: EXPERIMENTAL
Intervention: Mountainous setting (5-7 days stay, 600-900 m altitude)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Urban setting
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Mountainous setting
Number of subjects: 14
Study: 34107031

Group type: EXPERIMENTAL
Intervention: DASH + WM (Dietary Approaches to Stop Hypertension diet plus behavioral weight management)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: DASH (Dietary Approaches to Stop Hypertension diet)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 144
Study: 32409504

Group type: EXPERIMENTAL
Intervention: COVID-19 patients with diabetes
Number of subjects: 153

Group type: COMPARATOR
Intervention: COVID-19 patients without diabetes (control)
Number of subjects: 153
Study: 35441573

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Texture and colour enhancement imaging (TXI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: White-light imaging (WLI)
Number of subjects: 60
Study: 35509125

Group type: EXPERIMENTAL
Intervention: Dentin block (D-group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Autogenous bone block (A-group)
Number of subjects: 42
Study: 33879487

Group type: EXPERIMENTAL
Intervention: School-based pathway for identifying and supporting child anxiety difficulties, including screening and feedback to parents.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feedback from parents, children, and school staff on their experience with the pathway.
Number of subjects: 0
Study: 36113416

Group type: EXPERIMENTAL
Intervention: 3D guiding templates (3DGTs)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Free-hand technique (FH)
Number of subjects: 35
Study: 32755427

Group type: EXPERIMENTAL
Intervention: Interval Walking (IW)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Continuous Walking (CW)
Number of subjects: 16
Study: 34541889

Group type: EXPERIMENTAL
Intervention: Dry needling (DN) intervention group
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham dry needling (CG) control group
Number of subjects: 33
Study: 32484386

Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 34657137

Group type: EXPERIMENTAL
Intervention: Febuxostat treatment
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (lifestyle modification only)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 65
Study: 33233857

Group type: EXPERIMENTAL
Intervention: High blood eosinophils (≥8%)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Low blood eosinophils (<8%)
Number of subjects: 376
Study: 33742561

Group type: EXPERIMENTAL
Intervention: Retinal oxygen saturation (SatO2) assessment using Oxymap T1
Number of subjects: 41
Study: 33673910

Group type: EXPERIMENTAL
Intervention: Chronic unexplained GI symptoms over 20 years
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Symptom transitions
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Non-GI somatic symptom scores
Number of subjects: 228
Study: 33738034

Group type: EXPERIMENTAL
Intervention: Nimbex® (brand name cisatracurium)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cisatrex® (generic cisatracurium)
Number of subjects: 22
Study: 33561964

Group type: EXPERIMENTAL
Intervention: Rice bran dietary intervention (30 g over 24 hours for 24 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Rice powder (control group, 30 g over 24 hours for 24 weeks)
Number of subjects: 40
Study: 32186960

Group type: EXPERIMENTAL
Intervention: IL-4 gene rs2243291 genotype (C/G)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: TNF-α gene rs3093726 genotype (CT)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: TNF-α gene rs1800629 genotype
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: IL-10 gene rs1800896 genotype
Number of subjects: 369
Study: 34678863

Group type: EXPERIMENTAL
Intervention: Danzhi Xiaoyao Powder combined with escitalopram oxalate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Danzhi Xiaoyao Powder simulant combined with citalopram oxalate
Number of subjects: 0
Study: 32199509

Group type: EXPERIMENTAL
Intervention: Fluoxetine plus CBT
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 439

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 439
Study: 33206894

Group type: EXPERIMENTAL
Intervention: Theoretical-practical course-workshop (6 months duration)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (Unit A)
Number of subjects: 60
Study: 34526095

Group type: EXPERIMENTAL
Intervention: Early pharmacological treatment with ibuprofen (administered 24-72 hours postnatal age)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early pharmacological treatment with ibuprofen
Number of subjects: 0
Study: 32452128

Group type: EXPERIMENTAL
Intervention: Spironolactone (median dose 22.5 mg/day)
Number of subjects: 1767

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 1767

Group type: COMPARATOR
Intervention: Placebo (median dose 27.5 mg/day)
Number of subjects: 1767
Study: 35232809

Group type: EXPERIMENTAL
Intervention: Tofacitinib (TOF) 5 or 10 mg BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofacitinib (TOF) 5 mg BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab (ADA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofacitinib (TOF) 5 mg BID with methotrexate (MTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab (ADA) with MTX
Number of subjects: 0
Study: 32712591

Group type: EXPERIMENTAL
Intervention: Lumbar stabilization exercise and thoracic mobilization with strengthening exercises
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lumbar stabilization exercises
Number of subjects: 30
Study: 35973146

Group type: EXPERIMENTAL
Intervention: IBD&amp;me
Number of subjects: 152

Group type: COMPARATOR
Intervention: Biologics fact sheet
Number of subjects: 152
Study: 34342268

Group type: EXPERIMENTAL
Intervention: APPetite-mobile-app
Number of subjects: 157

Group type: COMPARATOR
Intervention: APPetite-food record
Number of subjects: 157

Group type: COMPARATOR
Intervention: 24-hour recall
Number of subjects: 157
Study: 32118387

Group type: EXPERIMENTAL
Intervention: Physical Exercise (EXE)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Interdisciplinary Treatment (INTER)
Number of subjects: 76
Study: 34433772

Group type: EXPERIMENTAL
Intervention: Personalized opioid tapering plan
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 110
Study: 32656706

Group type: EXPERIMENTAL
Intervention: New risk model for prognostic prediction after TAVR
Number of subjects: 388
Study: 33465342

Group type: EXPERIMENTAL
Intervention: High-dose prophylactic anticoagulation (either at intermediate or equivalent to therapeutic dose)
Number of subjects: 538

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: High-dose prophylactic anticoagulation
Number of subjects: 538
Study: 33452547

Group type: EXPERIMENTAL
Intervention: Group A (PLA plates sterilized using an autoclave program at 134 °C)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Group B (PLA plates seeded in different culture media)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Group C (PLA plates used for crystal violet stains on biofilms)
Number of subjects: 186
Study: 33950537

Group type: EXPERIMENTAL
Intervention: Online Counselling Group (OCG) - 26 subjects
Number of subjects: 53

Group type: COMPARATOR
Intervention: Waiting List Group (WLG) - 27 subjects
Number of subjects: 53
Study: 33165269

Group type: EXPERIMENTAL
Intervention: Slot-scanning technique
Number of subjects: 194

Group type: COMPARATOR
Intervention: Conventional radiography
Number of subjects: 194